Tenax Therapeutics, Inc. (TENX) Key Metrics
TENX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $50.9M
- Enterprise value
- −$46.3M
- P/E (TTM)
- —
- Forward P/E
- 0.3
- PEG ratio
- 1.44
- Price / sales
- 414.7
- Price / book
- 0.6
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.92
TENX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTENX valuation Price multiples at each fiscal year-end price.
TENX returns How much profit the business earns on the capital it uses.
TENX per-share figures Results divided by the shares outstanding at year-end.
TENX financial health Debt, liquidity and how easily interest is covered.
TENX valuation history
TENX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TENX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TENX cash returned to shareholders
TENX price vs earnings per share
TENX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $478.1M | $94.5M | — | — | — | — | — | — | — | — |
| Enterprise value | $380.5M | −$319,146 | — | — | — | — | — | — | — | — |
| Price / book | 4.9 | 1.0 | — | — | — | — | — | — | — | — |
| Earnings yield | −11.0% | −18.6% | — | — | — | — | — | — | — | — |
| Free cash flow yield | −7.5% | −15.7% | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $12.19 | $6.19 | $21.97 | $178.24 | $1,664.00 | $2,976.00 | $2,256.00 | $1,936.00 | $15,680.00 | $62,400.00 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Earnings per share | −$1.34 | −$1.15 | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$0.91 | −$0.97 | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$0.91 | −$0.97 | — | — | — | — | — | — | — | — |
| Cash per share | $2.49 | $6.21 | — | — | — | — | — | — | — | — |
| Book value per share | $2.48 | $6.02 | — | — | — | — | — | — | — | — |
| Tangible book value per share | $2.48 | $6.02 | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Shares outstanding | 39.2M | 15.3M | — | — | — | — | — | — | — | — |
| Change in shares outstanding | +156.8% | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −55.6% | −35.2% | −160.8% | −385.1% | −732.2% | −234.6% | −108.0% | −66.0% | −67.9% | −113.3% |
| Return on invested capital (ROIC) | — | — | — | — | — | — | — | — | −290.0% | −188.2% |
| Return on assets (ROA) | −52.4% | −32.5% | −102.2% | −235.1% | −505.0% | −148.9% | −85.2% | −58.7% | −53.2% | −91.2% |
| Return on tangible assets | −50.5% | −18.2% | −66.0% | −324.5% | −541.9% | −143.4% | −131.9% | −51.1% | −89.4% | — |
| Financial health | ||||||||||
| Total debt | — | — | $500,903 | $807,891 | $290,781 | $305,036 | $171,732 | — | $0 | $0 |
| Cash & short-term investments | $97.6M | $94.9M | $9.8M | $2.1M | $5.6M | $6.7M | $5.4M | $12.9M | $7.7M | $13.3M |
| Net debt | −$97.6M | −$94.9M | −$9.3M | −$1.3M | −$5.3M | −$6.4M | −$5.2M | −$12.9M | −$7.7M | −$13.3M |
| Debt / equity | — | — | 0.06 | 0.54 | 0.07 | 0.07 | 0.05 | — | 0.00 | 0.00 |
| Debt / assets | — | — | 0.04 | 0.24 | 0.05 | 0.04 | 0.03 | — | 0.00 | 0.00 |
| Current ratio | 14.56 | 20.60 | 3.26 | 1.74 | 3.64 | 3.21 | 2.44 | 8.51 | 7.99 | 2.20 |
| Quick ratio | 14.56 | 20.60 | 3.26 | 1.74 | 3.64 | 3.21 | 2.44 | 8.51 | 7.99 | 2.20 |
| Interest coverage | — | -847.6 | -343.6 | — | — | — | — | — | — | -1.6 |
| Working capital | $97.1M | $92.0M | $8.1M | $1.4M | $4.1M | $4.7M | $3.6M | $11.8M | $7.1M | $7.4M |
| Invested capital | −$494,000 | −$2.9M | −$1.2M | $176,950 | −$1.0M | −$1.8M | −$1.5M | −$1.1M | $1.2M | $3.9M |
| Tangible asset value | $97.1M | $92.0M | $8.1M | $1.5M | $4.2M | $4.6M | $3.8M | $11.8M | $8.9M | −$4.9M |
| Net current asset value | $97.1M | $92.0M | $8.1M | $1.3M | $3.9M | $4.6M | $3.6M | $11.8M | $7.1M | $7.4M |
| Graham net-net per share | $2.31 | $5.90 | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | $7.3M | $0 | $0 |
| Share buybacks (net) | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Capex / depreciation | — | 0.00 | 0.36 | 0.02 | 0.05 | 0.03 | 0.03 | 0.84 | 0.33 | 0.15 |
| Efficiency | ||||||||||
| Days payables outstanding | — | — | 60,790.9 | 2,106.4 | 2,708.6 | 3,847.1 | 4,101.3 | 27,565.8 | 17,946.7 | 16,371.1 |
| Receivables turnover | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Payables turnover | — | — | 0.01 | 0.17 | 0.13 | 0.09 | 0.09 | 0.01 | 0.02 | 0.02 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | — | — | — | — | — | — | $25,086 | $61,385 | $61,024 |
| Average payables | $4.6M | $2.6M | $1.3M | $654,032 | $808,747 | $1.2M | $1.2M | $680,838 | $669,730 | $850,041 |
| Average inventory | — | — | — | — | — | — | — | — | $0 | $82,167 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 94.3% |
Computed from TENX's annual financial statements (latest annual report filed March 10, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TENX valuation and financial ratios
Tenax Therapeutics earned a return on equity of −55.6% in fiscal 2025.
See the TENX income statement, the TENX chart for price history, or the TENX stock overview for the latest quote and news.
TENX key metrics FAQ
What is Tenax Therapeutics's return on equity?
Tenax Therapeutics's return on equity (ROE) was −55.6% in fiscal 2025: net income of -$52.6 million on average shareholders' equity of $94.5 million.
What is Tenax Therapeutics's free cash flow yield?
Tenax Therapeutics generated -$35.8 million of free cash flow in fiscal 2025, a free cash flow yield of −7.5% on its market value at year-end ($478.1 million).
What is Tenax Therapeutics's current ratio?
Tenax Therapeutics's current ratio was 14.56 at the end of fiscal 2025: current assets were 14.56 times current liabilities.